Prestige Consumer Healthcare Inc. to Release Fiscal 2022 Fourth Quarter and Year-End Earnings Results
Prestige Consumer Healthcare Inc. (NYSE:PBH) will issue its fiscal 2022 fourth quarter and year-end earnings on May 5, 2022, after market close. A conference call is scheduled for May 6 at 8:30 a.m. ET to discuss the results and company performance. Interested participants can join via phone or through an online webcast available on the company's Investor Relations page. Telephonic replays are accessible for a week post-call. Prestige Consumer Healthcare markets a variety of health products across North America and other markets.
- Scheduled earnings release for Q4 and year-end on May 5, 2022.
- Conference call on May 6 to discuss business attributes and results.
- None.
TARRYTOWN, N.Y., April 14, 2022 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2022 fourth quarter and year-end earnings release on Thursday, May 5, 2022 after the market close. The following morning, May 6, at 8:30 a.m. ET, the Company will host a conference call to discuss the results as well as for a discussion into the Company’s leading business attributes.
To participate via phone listeners calling from the U.S. and Canada may dial 844-233-9440, or 574-990-1016 internationally, using the conference ID 3389356. The Company will provide a live Internet webcast as well as an archived replay, which can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com.
Telephonic replays will be available for approximately one week following completion of the live call and can be accessed at 855-859-2056 within North America, and at 404-537-3406 from outside North America. The conference ID is 3389356.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819
irinquiries@prestigebrands.com
FAQ
When will Prestige Consumer Healthcare release its fourth quarter earnings?
What time is the conference call for Prestige Consumer Healthcare's earnings?
How can I participate in Prestige Consumer Healthcare's earnings call?
